[Therapy of carcinoid and the carcinoid syndrome].
D015119:Aminocaproic Acid / Q000627:therapeutic use; D007611:Aprotinin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000601:surgery*; D003533:Cyproheptadine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D010134:Fenclonine / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D007414:Intestinal Neoplasms / Q000601:surgery; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D008303:Malignant Carcinoid Syndrome / Q000628:therapy*; D008750:Methyldopa / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use
D003533:Cyproheptadine; D008750:Methyldopa; D004317:Doxorubicin; D007611:Aprotinin; D010134:Fenclonine; D005472:Fluorouracil; D015119:Aminocaproic Acid; D008784:Methysergide
Therapie des Karzinoids und Karzinoidsyndroms.